GlassScriptPhysician profile
Rosanna S Carter
NPI 1053789305
$8,613.94
in general payments reported to CMS, 2019-2025
17 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $1,043 · 2023: $2,144 · 2024: $2,571 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,817 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,816.61 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,985.56 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,638.98 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,621.65 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $903.97 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $830.15 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $461.32 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $373.07 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $261.68 | 2021-2025 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $149.46 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $95.22 | 2022-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.69 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $82.14 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $48.30 | 2022 | |
| Braeburn INC. | $22.53 | 2025 | Brixadi |
| Noven Therapeutics, LLC | $21.82 | 2024 | Secuado, Xelstrym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.00 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosanna Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.